Pfizer and Medivation Announce Trial Results of Huntington Disease Drug

Pfizer and Medivation announced results from the Phase 3 HORIZON trial of the investigational drug dimebon in patients with Huntington disease.

Pfizer Inc and Medivation, Inc. announced results from the Phase 3 HORIZON trial of the investigational drug dimebon (latrepirdine) in patients with Huntington disease. Dimebon did not achieve statistical significance for either of the co-primary endpoints, the Mini-Mental State Examination (MMSE), or the Clinician's Interview-Based Impression of Change, plus caregiver input (CIBIC-plus).

"We are disappointed with the results of the HORIZON trial given the high unmet need in this patient population. We will discontinue development of dimebon in Huntington disease, including the ongoing open-label extension study," said David Hung, M.D., president and chief executive officer of Medivation. "We will continue our ongoing 12-month Phase 3 CONCERT trial of dimebon and its open-label extension in patients with mild-to-moderate Alzheimer's disease. We expect to report to